Overview

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Status:
RECRUITING
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with NMIBC who have failed BCG therapy.
Phase:
PHASE1
Details
Lead Sponsor:
Ractigen Therapeutics.